Addressing the Treatment Gap in Ischemic Stroke
About this episode
The episode discusses the challenges and advancements in treating ischemic stroke, focusing on a new reversible thrombolytic developed by Basking Biosciences.
Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechanical thrombectomy because of the small treatment window. That’s because existing therapies require rapid presentation to specialized centers and carry nonreversible bleeding risks that make clinicians hesitant to use them. Basking Biosciences is developing a first-in-class, reversible thrombolytic that targets von Willebrand factor to expand access to safe, effective treatment. Basking Biosciences CEO Julia Owens and co-founder and chief scientific officer Shahid Nimjee discuss the tension between restoring blood flow and causing irreversible intracranial hemorrhage that clinicians face in treating ischemic stroke, the narrow treatment window for existing therapies, and how modulating von Willebrand factor may open a much larger treatment window across a broader range of care settings.
People in this episode
Guests: Julia Owens, Shahid Nimjee
Topics covered
- ischemic stroke
- treatment gap
- thrombolytic therapy
- blood flow restoration
- clinical challenges
Keywords
- ischemic stroke
- thrombolytic
- Basking Biosciences
- von Willebrand factor
- treatment window
- intracranial hemorrhage
- clot-busting drugs
Mentioned in this episode
Organizations: Basking Biosciences, von Willebrand factor
More episodes of The Bio Report
- Addressing a Data Problem to Enable AI-Drug Discovery
- Turning Multi Specific Antibody Design into an Engineering Discipline with AI
- A Pipeline in a Product that Reimagines Control of Inflammation
- Building a Genetics Engine to Crack the Target Bottleneck
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.